| Drug General Information |
| Drug ID |
D0RE4L
|
| Former ID |
DIB009433
|
| Drug Name |
KX2-361
|
| Indication |
Glioblastoma multiforme [ICD9: 191; ICD10:C71]
|
Phase 1 |
[1]
|
|---|
| Company |
Kinex pharmaceuticals
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Proto-oncogene tyrosine-protein kinase SRC |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
ErbB signaling pathway
|
|
Rap1 signaling pathway
|
|
Chemokine signaling pathway
|
|
Endocytosis
|
|
VEGF signaling pathway
|
|
Focal adhesion
|
|
Adherens junction
|
|
Tight junction
|
|
Gap junction
|
|
Platelet activation
|
|
GABAergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
Regulation of actin cytoskeleton
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Prolactin signaling pathway
|
|
Thyroid hormone signaling pathway
|
|
Oxytocin signaling pathway
|
|
Bacterial invasion of epithelial cells
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Tuberculosis
|
|
Hepatitis B
|
|
Viral carcinogenesis
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Angiogenesis
|
|
Cadherin signaling pathway
|
|
Integrin signalling pathway
|
|
Parkinson disease
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Endothelins
|
|
Signaling events mediated by PRL
|
|
LPA receptor mediated events
|
|
Atypical NF-kappaB pathway
|
|
Glypican 1 network
|
|
Plasma membrane estrogen receptor signaling
|
|
Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)
|
|
Signaling events mediated by PTP1B
|
|
S1P3 pathway
|
|
EPHB forward signaling
|
|
Nectin adhesion pathway
|
|
Regulation of p38-alpha and p38-beta
|
|
CDC42 signaling events
|
|
Signaling events regulated by Ret tyrosine kinase
|
|
Arf6 signaling events
|
|
Signaling events mediated by TCPTP
|
|
FAS (CD95) signaling pathway
|
|
Thromboxane A2 receptor signaling
|
|
Netrin-mediated signaling events
|
|
Alpha9 beta1 integrin signaling events
|
|
CXCR4-mediated signaling events
|
|
EGF receptor (ErbB1) signaling pathway
|
|
Class I PI3K signaling events
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Regulation of Androgen receptor activity
|
|
E-cadherin signaling in the nascent adherens junction
|
|
amb2 Integrin signaling
|
|
Integrins in angiogenesis
|
|
ErbB1 downstream signaling
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
ErbB2/ErbB3 signaling events
|
|
EPHA forward signaling
|
|
E-cadherin signaling in keratinocytes
|
|
PDGFR-beta signaling pathway
|
|
Nongenotropic Androgen signaling
|
|
Internalization of ErbB1
|
|
CXCR3-mediated signaling events
|
|
Signaling events mediated by VEGFR1 and VEGFR2
|
|
Syndecan-2-mediated signaling events
|
|
Class I PI3K signaling events mediated by Akt
|
|
Syndecan-3-mediated signaling events
|
|
Ephrin B reverse signaling
|
|
Trk receptor signaling mediated by PI3K and PLC-gamma
|
|
EPHA2 forward signaling
|
|
Alpha-synuclein signaling
|
|
FGF signaling pathway
|
|
Alpha4 beta1 integrin signaling events
|
|
Signaling events mediated by focal adhesion kinase
|
|
WikiPathways
|
ErbB Signaling Pathway
|
|
Senescence and Autophagy in Cancer
|
|
Notch Signaling Pathway
|
|
EPO Receptor Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
TGF beta Signaling Pathway
|
|
Signaling of Hepatocyte Growth Factor Receptor
|
|
Kit receptor signaling pathway
|
|
Pregnane X Receptor pathway
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
IL-3 Signaling Pathway
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Polycystic Kidney Disease Pathway
|
|
Alpha 6 Beta 4 signaling pathway
|
|
BDNF signaling pathway
|
|
Integrated Pancreatic Cancer Pathway
|
|
Oncostatin M Signaling Pathway
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
Signaling Pathways in Glioblastoma
|
|
TSLP Signaling Pathway
|
|
Arylhydrocarbon receptor (AhR) signaling pathway
|
|
Regulation of Microtubule Cytoskeleton
|
|
FSH signaling pathway
|
|
Leptin signaling pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Integrin-mediated Cell Adhesion
|
|
Angiogenesis
|
|
Androgen receptor signaling pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02326441) Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies. U.S. National Institutes of Health. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2206). |
|---|
